This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of
zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and
older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total
of 3500 participants will be enrolled and randomized in the United States. Participants,
follow-up outcome assessors, and study investigators will be blinded to assigned study
treatment. This trial is funded by the National Institute of Aging.
Phase:
Phase 4
Details
Lead Sponsor:
California Pacific Medical Center Research Institute
Collaborators:
Duke University National Institute on Aging (NIA) Parkinson's Foundation University of California, San Francisco University of Pittsburgh